VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2021 | Dato-DXd: a new ADC on the block

Sara Tolaney, MD, Dana Farber Cancer Institute, Boston, MA, discusses the preliminary results from an ongoing Phase I study evaluating datopotamab deruxtecan (Dato-DXd), a Trop2-directed antibody-drug conjugate (ADC) for patients with triple-negative (TNBC) breast cancer. This novel agent was associated with a response rate of over 40% in this heavily pre-treated metastatic TNBC population, and had a tolerable toxicity profile. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

Disclosures

Sara Tolaney, MD, has received institutional research funds and honoraria from AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genenrach/Roche, Immunomedics/Gi lead, Exelixis and Brsitol-Myers Squibb.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter